M06
Conditions
Interventions
Group 1: 1) Newly diagnosed RA / therapy naive.
2) Active: initial diagnosis >1 year
categorization according to DAS28.
3) Remission: initial diagnosis > 1 year
categorization according to DAS28
Assessments:
1) Demographic data including smoking status, medication, previous pulmonary findings and comorbidities will be collected.
2) Documentation of RA:
- Ac
no symptoms of muscle disease
no history of rheumatologic disease or muscle disease.
Assessments:
1) Demographic data including smoking status, medication, previous pulmonary findings and comorbidities will be collected.
2) Docu
Sponsors
Lungenklinik, Kliniken der Stadt Köln gGmbH
Eligibility
Sex/Gender
All
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: Rheumatoid arthritis patients = 18 years of age who are able to give informed consent are included in the study. The diagnosis of RA must have been made according to the guideline ACR/EULAR criteria from 2010. For data collection and later analysis, rheumatoid arthritis patients will be divided into the above 3 categories. Control group: Healthy subjects, age =18 years; no symptoms of muscle disease; no history of rheumatologic disease or muscle disease; Subjects will be asked not to undergo exhaustive physical exertion, smoke or consume large amounts of alcohol 24 hours before the examination.
Exclusion criteria
Exclusion criteria: Exclusion criteria both groups: Specific pre-existing conditions: Chronic alcohol abuse, neuromuscular disease, COPD, severe heart failure (with an ejection fraction (EF) = 40%) diaphragmatic paresis, pulmonary hypertension, uncontrolled bronchial asthma, diabetes mellitus with polyneuropahtia; active malignancy, hypoventilation syndrome, obesity with BMI = 35kg/m² or an exacerbation of rheumatoid arthritis or other underlying disease. Before ordering the 6-minute walk test, the medical staff must check whether there is an increased risk of falls for the patient. If this is the case, it is considered a criterion for exclusion. Medication in the last 12 months: Therapy with oral corticosteroid within the last 12 months to an extent that could affect muscle strength. Drug use <18 years of age Inability to consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Is there a reduction in respiratory muscle strength measured by peak inspiratory mouth closure pressure (PImax peak = primary endpoint) as an expression of global respiratory muscular strength in rheumatoid arthritis patients:irrespective of the stage of their disease compared to healthy individuals. | — |
Secondary
| Measure | Time frame |
|---|---|
| A) Comparison between patient group and control group. - Other respiratory muscular function parameters - Hand muscle strength - Lung function parameters B) Influence of functional parameters (lung function, respiratory muscle function, hand muscle strength) on clinical patient-relevant outcomes. C) Comparison of the patient group and in the control group - Relationship between respiratory muscle strength and hand muscle strength | — |
Countries
Germany
Contacts
Public ContactMelanie Berger
Lungenklinik, Kliniken der Stadt Köln gGmbH
Outcome results
None listed